In this interview, CEO Sara Barrington of Verici DX – an advanced medical diagnostics firm focusing on the global kidney transplant market - takes me through today’s strong H1’24 results and multiple value catalysts ahead for the business.
00:00 Recap of #VRCI’s unique technology and USPs
05:30 Ground breaking licensing deal with Thermo Fisher Scientific.
09:35 Commercialisation of Tutivia & Protega validation test
17:00 Services, placing, cash runway & outlook
Disclosure: Verici is a Vox Markets client
Q&A with Verici DX CEO, Sara Barrington
Теги
small capssmall caps investingVox MarketsLondon Stock ExchangeFinancial NewsCompany Newstradinginvestingstockssharesmoneyuksmall cap investingAIMStock MarketInvesting for beginnersstock recommendationskey takeaways stock marketfinancial markets podcaststock market commentaryfinancial market economicsstock trading strategiesstock market analysisVRCIVerici DX